About the Company
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on FRACTYL HEALTH, INC.
Fractyl Health Drops 26% Pre-Market: What You Need to Know
On the same day, Fractyl also reported encouraging two-year real-world clinical data on its Revita DMR treatment, developed ...
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed ...
Fractyl Health Announces Proposed Public Offering
Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering ...
Fractyl Health Reports Q2 2025 Financial Results and Progress
Fractyl Health, Inc. ( ($GUTS) ) has released its Q2 earnings. Here is a breakdown of the information Fractyl Health, Inc. presented to its ...
Fractyl Health’s Earnings Call: Strategic Gains Amid Financial Challenges
Fractyl Health, Inc. (($GUTS)) has held its Q2 earnings call. Read on for the main highlights of the call. Fractyl Health’s recent earnings call ...
Fractyl Health to Present New Preclinical Data on Sustained Weight ...
BURLINGTON, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root ...
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ: GUTS) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO ...
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 ...
BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the ...
Fractyl Health Highlights Urgent Demand for Weight Maintenance ... - Nasdaq
Fractyl Health, Inc. announced significant progress in its pivotal REMAIN-1 study, aimed at maintaining weight loss after discontinuing GLP-1 drugs, driven by strong demand from patients and ...
Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) Q1 2025 Earnings Call ...
Fractyl Health, Inc. Common Stock reports earnings inline with expectations. Reported EPS is $-0.49 EPS, expectations were $-0.49. Operator: Good afternoon. And welcome to Fractyl Health’s First ...
Fractyl Health Inc. - Page 1 | BioWorld
BioWorld Content on 'Fractyl Health Inc.'Biopharma IPOs have faced tough conditions in recent years, but 2024 is showing signs of improvement in terms of value, while stumbling on overall performance.
Similar Companies
Loading the latest forecasts...